• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

年龄会改变肢端肥大症术后患者口服葡萄糖后平均生长激素水平和生长激素最低点水平的诊断准确性。

Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.

作者信息

Colao Annamaria, Pivonello Rosario, Cavallo Luigi M, Gaccione Maria, Auriemma Renata S, Esposito Felice, Cappabianca Paolo, Lombardi Gaetano

机构信息

Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, Naples, Italy.

出版信息

Clin Endocrinol (Oxf). 2006 Aug;65(2):250-6. doi: 10.1111/j.1365-2265.2006.02584.x.

DOI:10.1111/j.1365-2265.2006.02584.x
PMID:16886969
Abstract

BACKGROUND

This analytical, retrospective study was designed to select cut-off thresholds of mean GH levels during a diurnal profile and nadir GH levels after oral glucose tolerance test (OGTT) according to age to diagnose surgical remission of acromegaly.

METHODS

One hundred forty-one patients (76 women, aged 44 +/- 15 years and 65 men, aged 43 +/- 13 years) were included in this study. For the purpose of this study, remission was based on insulin-like growth factor-I (IGF-I) levels in the normal range for age. Diagnostic accuracy was analysed by receiving-operator characteristics (ROC) curves in the entire series, and in young (20-40 years), middle-aged (41-60 years) and older patients (> 60 years), separately.

RESULTS

Sixty patients (42.6%) had normal IGF-I levels after surgery. In the entire series, in young and in middle-aged patients, the ROC analysis showed that optimum cut-off for mean GH levels was 2.3 microg/l (diagnostic accuracy range, 94-97%) whereas that for nadir GH after OGTT were, respectively, 0.85, 0.9 and 0.8 microg/l (diagnostic accuracy range, 90-95%). In the older patients, the optimum cut-off selected for mean GH levels was 1.4 microg/l and that for nadir GH after OGTT was 0.5 microg/l (diagnostic accuracy, 100% for both). The comparative analysis of the ROC curves did not show any significant difference between mean GH and nadir GH after OGTT (P = 0.21).

CONCLUSIONS

The criteria currently accepted for diagnosing post-surgical remission of acromegaly have high diagnostic accuracy only in the patients aged below 60 years. In older patients, lower cut-offs (i.e. = 1.4 microg/l for fasting GH and = 0.5 microg/l for nadir GH after OGTT) predict normal IGF-I levels. Mean GH levels during a diurnal profile have similar diagnostic accuracy of nadir GH levels after OGTT. This suggests that OGTT is not necessary to establish surgical cure.

摘要

背景

本分析性回顾性研究旨在根据年龄选择昼夜生长激素(GH)水平曲线的平均GH水平及口服葡萄糖耐量试验(OGTT)后GH最低点水平的截断阈值,以诊断肢端肥大症手术缓解情况。

方法

本研究纳入了141例患者(76例女性,年龄44±15岁;65例男性,年龄43±13岁)。本研究中,缓解基于年龄对应的胰岛素样生长因子-I(IGF-I)水平在正常范围内。通过受试者工作特征(ROC)曲线分析整个队列以及分别在年轻(20 - 40岁)、中年(41 - 60岁)和老年患者(>60岁)中的诊断准确性。

结果

60例患者(42.6%)术后IGF-I水平正常。在整个队列、年轻和中年患者中,ROC分析显示,昼夜GH平均水平的最佳截断值为2.3μg/L(诊断准确性范围为94 - 97%),而OGTT后GH最低点水平分别为0.85、0.9和0.8μg/L(诊断准确性范围为90 - 95%)。在老年患者中,昼夜GH平均水平的最佳截断值为1.4μg/L,OGTT后GH最低点水平为0.5μg/L(两者诊断准确性均为100%)。ROC曲线的比较分析显示,OGTT后GH平均水平与最低点水平之间无显著差异(P = 0.21)。

结论

目前用于诊断肢端肥大症术后缓解的标准仅在60岁以下患者中具有较高的诊断准确性。在老年患者中,较低的截断值(即空腹GH = 1.4μg/L,OGTT后GH最低点 = 0.5μg/L)可预测IGF-I水平正常。昼夜GH平均水平与OGTT后GH最低点水平具有相似的诊断准确性。这表明OGTT对于确定手术治愈并非必要。

相似文献

1
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.年龄会改变肢端肥大症术后患者口服葡萄糖后平均生长激素水平和生长激素最低点水平的诊断准确性。
Clin Endocrinol (Oxf). 2006 Aug;65(2):250-6. doi: 10.1111/j.1365-2265.2006.02584.x.
2
Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.口服葡萄糖后 GH 水平和 IGF-I 水平不一致,且肢端肥大症患者经治疗后 GH 水平降低:轻度疾病活动的生化标志物的精细化。
Horm Metab Res. 2010 Jan;42(1):50-5. doi: 10.1055/s-0029-1239522. Epub 2009 Oct 1.
3
Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?肢端肥大症生化缓解的临床指标:疾病控制不完全是否总是意味着治疗失败?
Clin Endocrinol (Oxf). 2005 Apr;62(4):410-7. doi: 10.1111/j.1365-2265.2005.02233.x.
4
Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.肢端肥大症的术前奥曲肽治疗:最终生长激素(GH)浓度和垂体功能无改善。一项长期病例对照研究。
Acta Neurochir (Wien). 2005 May;147(5):485-93; discussion 493. doi: 10.1007/s00701-005-0511-9. Epub 2005 Apr 4.
5
The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.奥曲肽试验剂量后生长激素的最低点可预测生长抑素类似物治疗肢端肥大症的长期疗效。
Clin Endocrinol (Oxf). 2005 Jun;62(6):742-7. doi: 10.1111/j.1365-2265.2005.02278.x.
6
Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism.原发性甲状旁腺功能亢进患者口服葡萄糖后生长激素及胰岛素样生长因子结合蛋白-1的反应
Clin Endocrinol (Oxf). 2006 Jul;65(1):27-34. doi: 10.1111/j.1365-2265.2006.02541.x.
7
Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.通过单次血样评估肢端肥大症的疾病活动:葡萄糖负荷后120分钟值与自发性生长激素分泌及胰岛素样生长因子系统的比较
Clin Endocrinol (Oxf). 2004 Jul;61(1):138-44. doi: 10.1111/j.1365-2265.2004.02064.x.
8
Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.通过测量肢端肥大症患者术后即刻生长激素水平和口服葡萄糖耐量试验预测长期缓解。
Neurosurgery. 2012 May;70(5):1106-13; discussion 1113. doi: 10.1227/NEU.0b013e31823f5c16.
9
The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.常规放疗对生长激素分泌型垂体腺瘤患者的长期疗效。
Clin Endocrinol (Oxf). 2005 Feb;62(2):210-6. doi: 10.1111/j.1365-2265.2005.02199.x.
10
Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?使用灵敏的生长激素检测法评估经治疗的肢端肥大症患者的疾病活动度:生化治愈是否应达到严格的正常生长激素水平?
J Clin Endocrinol Metab. 2002 Jul;87(7):3142-7. doi: 10.1210/jcem.87.7.8631.

引用本文的文献

1
Acromegaly: diagnostic challenges and individualized treatment.肢端肥大症:诊断挑战与个体化治疗
Expert Rev Endocrinol Metab. 2025 Jan;20(1):63-85. doi: 10.1080/17446651.2024.2448784. Epub 2025 Jan 5.
2
Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly.使用现代检测方法和参考范围解读生长激素和 IGF-1 结果,以监测肢端肥大症的治疗效果。
Front Endocrinol (Lausanne). 2023 Oct 25;14:1266339. doi: 10.3389/fendo.2023.1266339. eCollection 2023.
3
Correlation Between Clinical and Biochemical Markers in Patients With Acromegaly on Different Modalities of Treatment.
肢端肥大症患者不同治疗方式下临床与生化指标的相关性
Cureus. 2021 Nov 10;13(11):e19438. doi: 10.7759/cureus.19438. eCollection 2021 Nov.
4
Biochemical investigations in diagnosis and follow up of acromegaly.肢端肥大症诊断与随访中的生化检查
Pituitary. 2017 Feb;20(1):33-45. doi: 10.1007/s11102-017-0792-z.
5
Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.口服葡萄糖耐量试验中生长激素最低点水平与腺瘤切除术后3个月时胰岛素样生长因子-1值不一致的肢端肥大症患者的临床特征和自然病程。
Neurosurg Rev. 2016 Apr;39(2):313-8; discussion 318-9. doi: 10.1007/s10143-015-0692-5. Epub 2016 Jan 20.
6
Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of Disease.根据新提出的疾病控制共识标准,对长期缓解的肢端肥大症患者进行重新评估。
Int J Endocrinol. 2014;2014:581594. doi: 10.1155/2014/581594. Epub 2014 Dec 21.
7
Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.口服葡萄糖负荷后生长激素的值在长期生长抑素受体配体治疗的肢端肥大症患者中没有提供临床有用的信息。
Endocrine. 2014 Feb;45(1):122-7. doi: 10.1007/s12020-013-9996-9. Epub 2013 Jun 21.
8
Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.口服葡萄糖负荷和胰岛素样生长因子 I 评估生长抑素类似物治疗肢端肥大症时的生化控制情况。
J Endocrinol Invest. 2011 Oct;34(9):e291-5. doi: 10.3275/7802. Epub 2011 Jun 21.
9
The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.2008 年内分泌肿瘤峰会:评估肢端肥大症和类癌综合征的治疗方法。
Pituitary. 2010 Sep;13(3):266-86. doi: 10.1007/s11102-009-0210-2.
10
Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?肢端肥大症的监测:当生长激素(GH)和胰岛素样生长因子-1(IGF-1)水平不一致时应进行哪些检查?
Clin Endocrinol (Oxf). 2009 Aug;71(2):166-70. doi: 10.1111/j.1365-2265.2009.03556.x. Epub 2009 Feb 18.